MARKET

IMMX

IMMX

Immix Biopharma Inc
NASDAQ
9.94
-0.16
-1.58%
After Hours: 10.00 +0.06 +0.60% 16:25 05/15 EDT
OPEN
10.03
PREV CLOSE
10.10
HIGH
10.08
LOW
9.56
VOLUME
603.25K
TURNOVER
--
52 WEEK HIGH
11.61
52 WEEK LOW
1.870
MARKET CAP
540.85M
P/E (TTM)
-10.9665
1D
5D
1M
3M
1Y
5Y
1D
Immix Biopharma posts corporate presentation on NXC-201 CAR-T for relapsed AL amyloidosis
PUBT · 1d ago
Immix Biopharma posts corporate presentation on NXC-201 CAR-T for relapsed AL amyloidosis
PUBT · 3d ago
Weekly Report: what happened at IMMX last week (0504-0508)?
Weekly Report · 5d ago
Immix Biopharma Q1 net loss widens to USD 10.09 million
PUBT · 05/07 22:20
Immix Biopharma publishes corporate presentation on NXC-201 CAR-T in relapsed AL amyloidosis
PUBT · 05/04 18:15
Weekly Report: what happened at IMMX last week (0427-0501)?
Weekly Report · 05/04 10:34
Immix Biopharma publishes corporate presentation on NXC-201 CAR-T in relapsed AL amyloidosis
PUBT · 05/03 15:36
Weekly Report: what happened at IMMX last week (0420-0424)?
Weekly Report · 04/27 10:38
More
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

Webull offers Immix Biopharma Inc stock information, including NASDAQ: IMMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMX stock methods without spending real money on the virtual paper trading platform.